Cliff Myers Email

VP, Head KCT Marketing at Exelixis . Exelixis

Current Roles

Employees:
1919
Revenue:
$1.3B
About
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally. We are steadfast in our commitment to prudently reinvest in our business to maximize the potential of our pipeline. We intend to supplement our existing therapeutic assets with targeted business development activities and internal drug discovery all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis recently earned a spot on Deloitte's Technology Fast 500 list, a yearly award program honoring the 500 fastest-growing companies over the past four years. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Exelixis Address
1851 Harbor Bay Parkway
Alameda, CA
United States
Exelixis Email

Past Companies

ExelixisVice President, Head of KCT Marketing at Exelixis
ExelixisExecutive Director, Key Customer Team
GenentechNational Thought Leader Liaison, Melanoma

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.